Medicare Enrolled
Dr. Robert Fein, MD
Hematology & Oncology · Somerset, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Fein from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Fein?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Fein
Dr. Robert Fein is a hematology & oncology specialist in Somerset, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Fein performed 105,572 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Fein received a total of $3,978 from 54 pharmaceutical and/or device companies across 163 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Fein is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 8% volume in NJ
$3,978 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗105,572
Medicare services
Top 8% in NJ for hematology & oncology
Not available
Unique patients (not deduplicated)
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
53,250 | $1 | $3 |
| Pembrolizumab injection (Keytruda) | 12,200 | $43 | $161 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
10,800 | $0 | $1 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
8,640 | $2 | $10 |
| Denosumab injection (Prolia/Xgeva) | 6,720 | $18 | $68 |
| Eflapegrastim injection, 0.1 mg An injection of eflapegrastim-xnst administered at a dose of 0.1 mg. |
2,376 | $25 | $96 |
| Injection, fulvestrant, 25 mg | 1,550 | $8 | $54 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,302 | $0 | $0 |
| Iron infusion (Monoferric) | 1,300 | $17 | $64 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,248 | $8 | $30 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,084 | $103 | $421 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
936 | $8 | $23 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
384 | $12 | $48 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
352 | $26 | $101 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
338 | $75 | $299 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
331 | $6 | $14 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
308 | $66 | $250 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
280 | $119 | $468 |
| Anti-nausea injection (ondansetron/Zofran) | 278 | $0 | $0 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 231 | $3 | $11 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
223 | $57 | $229 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
201 | $2 | $8 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
184 | $28 | $116 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
108 | $1 | $3 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 101 | $332 | $1,500 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
93 | $58 | $228 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
80 | $18 | $70 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
79 | $1 | $4 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
74 | $14 | $53 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
70 | $150 | $589 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
50 | $1 | $8 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
49 | $11 | $44 |
| New patient office visit, complex (60-74 min) | 49 | $188 | $719 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
47 | $1 | $6 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
40 | $41 | $153 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
36 | $109 | $419 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
32 | $3 | $10 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
31 | $135 | $547 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
27 | $30 | $113 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
27 | $65 | $268 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
23 | $23 | $100 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
20 | $36 | $202 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
20 | $144 | $588 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
52.7% high complexity
42.9% medium
4.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,978
Total received (2018-2024)
Avg $568/year across 7 years
Top 45% in NJ for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
54
Companies
163
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,138
2023
$1,019
2022
$502
2021
$26
2020
$462
2019
$477
2018
$354
Payments by company (2024)
Bayer Healthcare Pharmaceuticals Inc.
$90
Regeneron Healthcare Solutions, Inc.
$85
Mirati Therapeutics, Inc.
$73
PFIZER INC.
$60
Novartis Pharmaceuticals Corporation
$55
Janssen Biotech, Inc.
$52
Merck Sharp & Dohme LLC
$52
Daiichi Sankyo Inc.
$48
Stemline Therapeutics Inc.
$45
Blueprint Medicines Corporation
$45
Apellis Pharmaceuticals, Inc.
$38
Incyte Corporation
$36
Ipsen Biopharmaceuticals, Inc
$34
Boehringer Ingelheim Pharmaceuticals, Inc.
$34
Astellas Pharma US Inc
$33
BeiGene USA, Inc.
$33
Octapharma USA, Inc.
$32
AstraZeneca Pharmaceuticals LP
$31
Aveo Pharmaceuticals, Inc.
$29
Adaptive Biotechnologies Corporation
$27
ARRAY BIOPHARMA INC
$22
Pharmacosmos Therapeutics Inc.
$20
PUMA BIOTECHNOLOGY, INC.
$18
Dendreon Pharmaceuticals LLC
$18
Genentech USA, Inc.
$17
Celgene Corporation
$17
Gilead Sciences, Inc.
$17
SOBI, INC
$17
Lilly USA, LLC
$16
GlaxoSmithKline, LLC.
$16
E.R. Squibb & Sons, L.L.C.
$15
Alnylam Pharmaceuticals Inc.
$14
Top 3 companies account for 21.8% of 2024 payments
All-time payments by company (2018-2024) ›
Daiichi Sankyo Inc.
$632
E.R. Squibb & Sons, L.L.C.
$291
Amgen Inc.
$192
PFIZER INC.
$155
Bayer Healthcare Pharmaceuticals Inc.
$151
Blueprint Medicines Corporation
$138
Karyopharm Therapeutics Inc.
$137
Exelixis Inc.
$128
Epizyme, Inc.,
$125
Astellas Pharma US Inc
$111
Janssen Biotech, Inc.
$102
Mirati Therapeutics, Inc.
$94
AstraZeneca Pharmaceuticals LP
$86
Regeneron Healthcare Solutions, Inc.
$85
Merck Sharp & Dohme LLC
$84
Incyte Corporation
$81
Bayer HealthCare Pharmaceuticals Inc.
$80
Gilead Sciences, Inc.
$73
Genentech USA, Inc.
$71
Novartis Pharmaceuticals Corporation
$68
GlaxoSmithKline, LLC.
$66
Pharmacosmos Therapeutics Inc.
$62
Janssen Scientific Affairs, LLC
$59
Celgene Corporation
$51
Merck Sharp & Dohme Corporation
$51
Ipsen Biopharmaceuticals, Inc
$49
Boehringer Ingelheim Pharmaceuticals, Inc.
$48
Stemline Therapeutics Inc.
$45
ADC Therapeutics America, Inc.
$42
EMD Serono, Inc.
$40
AbbVie, Inc.
$38
Apellis Pharmaceuticals, Inc.
$38
GENZYME CORPORATION
$37
Alexion Pharmaceuticals, Inc.
$36
Takeda Pharmaceuticals U.S.A., Inc.
$36
BeiGene USA, Inc.
$33
Octapharma USA, Inc.
$32
Seattle Genetics, Inc.
$29
Aveo Pharmaceuticals, Inc.
$29
Lilly USA, LLC
$28
Adaptive Biotechnologies Corporation
$27
ARRAY BIOPHARMA INC
$22
Emmaus Medical, Inc.
$20
Eisai Inc.
$19
PUMA BIOTECHNOLOGY, INC.
$18
Dendreon Pharmaceuticals LLC
$18
Agios Pharmaceuticals, Inc.
$17
SOBI, INC
$17
ABBVIE INC.
$15
Kyowa Kirin, Inc.
$15
TOLMAR Pharmaceuticals, Inc.
$15
Jazz Pharmaceuticals Inc.
$15
Alnylam Pharmaceuticals Inc.
$14
EISAI INC.
$14
Top 3 companies account for 28.0% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · Aliqopa · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · COSELA · Cabometyx · DARZALEX · DOPTELET · ELIGARD · ELIQUIS · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · Empaveli · Endari · Enhertu · FARESTON · FOTIVDA · GILOTRIF · GIVLAARI · Gazyva · IBRANCE · INJECTAFER · INLYTA · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LUMAKRAS · Lenvima · MONOFERRIC · MVASI · NUCALA · Nubeqa · OJJAARA · OPDIVO · Onivyde · Orserdu · PADCEV · PANZYGA · PLUVICTO · PROVENGE · PYRUKYND · Padcev · Phesgo · REBLOZYL · SIMPONI ARIA · SOMATULINE DEPOT · SPRYCEL · Stivarga · TAGRISSO · TAZVERIK · TECENTRIQ · TECVAYLI · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VYXEOS · Venclexta · XALKORI · XPOVIO · XTANDI · Xofigo · Xospata · ZEJULA · clonoSEQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
186
County median income
$135,960
Nearest hospital to ZIP centroid (approximate)
UNIVERSITY BEHAVIORAL HEALTH CARE
4.6 mi
4.6 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Fein is a mixed practice specialist, with above-average Medicare volume (top 8% in NJ), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Fein experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Fein performed 53,250 iron infusion (injectafer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Fein receive payments from pharmaceutical companies?
Yes. Dr. Fein received a total of $3,978 from 54 companies across 163 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Fein's costs compare to other hematology & oncology specialists in Somerset?
Dr. Fein's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Fein) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Somerset
Browse hematology & oncology specialists in Somerset ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology